Eisai receives positive CHMP opinion for Lecanemab in early Alzheimer’s disease
Eisai (ESAIY) and Biogen (BIIB) announced that a positive opinion has been received from the Committee for Medicinal Products for Human Use of ...
EMA recommends Leqembi for treatment of early Alzheimer’s disease
After re-examining its initial opinion, EMA’s human medicines committee, or CHMP, has recommended granting a marketing authorisation to Leqembi for treating mild cognitive impairment or mild dementia ...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...
CHMP issues positive recommendation for approval of lecanemab in the EU
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai ...
The EMBO Journal2 小时
Diagnosis and prognosis prediction of gastric cancer by high-performance serum lipidome ...
Novel liquid biopsy tools allowing for diagnosis and prognostic prediction for gastric cancer (GC) patients are urgently ...
Krone1 小时
EU: First green light for Alzheimer’s therapy
The European Medicines Agency (EMA) has given the green light for the first Alzheimer's therapy in the EU that targets the ...
TCTMD22 小时
High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low
While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.